<DOC>
	<DOCNO>NCT02886702</DOCNO>
	<brief_summary>A Multi-Center , Double-Blind , Randomized , Vehicle-Controlled , Parallel-Group Study Comparing Tazarotene Cream 0.05 % TAZORAC® ( tazarotene ) Cream 0.05 % Both Active Treatments Vehicle Control Treatment Stable Plaque Psoriasis</brief_summary>
	<brief_title>A Study Comparing Tazarotene Cream 0.05 % TAZORAC® ( Tazarotene ) Cream 0.05 % Both Placebo Control Treatment Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Tazarotene</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Have definite clinical diagnosis stable ( least 6 month ) plaque psoriasis , involve least 2 % 20 % body surface area ( BSA ) ( include scalp intertriginous area ) Have minimum plaque elevation target lesion site least moderate severity ( grade ≥ 3 Psoriasis Area Severity Index [ PASI ] ) . The severe lesion baseline identify target lesion Have Investigator 's Global Assessment ( IGA ) disease severity least moderate ( score ≥ 3 ) overall assessment lesion treat . A female subject pregnant , nursing , plan pregnancy , agree use acceptable form birth control within study participation period Have current diagnosis unstable form psoriasis treatment area , include pustular , guttate , exfoliative erythrodermic psoriasis Have history psoriasis unresponsive topical treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>